Deep learning with feature embedding for compound-proteininteraction prediction
Abstract
Accurately identifying compound-protein interactions in silico can deepen our understanding of the mechanisms of drug action and significantly facilitate the drug discovery and development process. Traditional similarity-based computational models for compound-protein interaction prediction rarely exploit the latent features from current available large-scale unlabelled compound and protein data, and often limit their usage on relatively small-scale datasets. We propose a new scheme that combines feature embedding (a technique of representation learning) with deep learning for predicting compound-protein interactions. Our method automatically learns the low-dimensional implicit but expressive features for compounds and proteins from the massive amount of unlabelled data. Combining effective feature embedding with powerful deep learning techniques, our method provides a general computational pipeline for accurate compound-protein interaction prediction, even when the interaction knowledge of compounds and proteins is entirely unknown. Evaluations on current large-scale databases of the measured compound-protein affinities, such as ChEMBL and BindingDB, as well as known drug-target interactions from DrugBank have demonstrated the superior prediction performance of our method, and suggested that it can offer a useful tool for drug development and drug repositioning.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 93
- Assay
- Research Focus
- Approach
Abstract summary
Claude Opus 5.5 · xhigh effort · 18 Oct 2026 · from the abstract · CC BY-NC-ND 4.0
Compound and protein embeddings learned from unlabelled data feed a deep network for compound-protein interaction prediction, reported to perform better on ChEMBL, BindingDB and DrugBank.
Similarity-based predictors of compound-protein interaction make little use of the large unlabelled compound and protein collections already available and are typically run on small datasets. Learning representations from that unlabelled material is proposed as a way to scale up and to handle compounds or proteins with no recorded interactions.
Key results
ClaimedA pipeline learns low-dimensional embeddings of compounds and proteins from large unlabelled collections by representation learning and feeds them to deep neural networks that predict interactions.
Described as the method's design; the abstract gives no architecture, embedding dimensionality, training procedure or size of the unlabelled corpora. · Abstract
ClaimedThe authors report better prediction than existing approaches on affinity databases and on known drug-target pairs.
Evaluations are said to use measured affinities from ChEMBL and BindingDB and drug-target interactions from DrugBank; no metric, score, baseline method, data split or statistical comparison is reported. · Abstract
ClaimedThe approach is said to work even when nothing is known about the interactions of the compound or protein in question, which would cover cold-start cases in drug repositioning.
Stated as a property of the pipeline; the abstract describes no experiment isolating unseen compounds or unseen proteins and gives no performance under that setting. · Abstract
Methods, data and reproducibility
Feature embedding (representation learning) is applied to large unlabelled compound and protein data to produce compact feature vectors, which are then used by deep learning models to predict compound-protein interactions; the pipeline is evaluated against affinity and drug-target databases.
- measured compound-protein affinities from ChEMBL
- measured compound-protein affinities from BindingDB
- known drug-target interactions from DrugBank
- unlabelled compound and protein data used to learn the embeddings
- Methods & tools
- ChEMBL, BindingDB, DrugBank, deep neural networks, feature embedding (representation learning)
- Reproducibility gaps
- No repository, implementation details or dataset versions are named in the abstract.
Limitations (2)
- No accuracy figures, baseline methods, data splits or ablations appear in the available text, so the claim of better performance cannot be assessed at all. · noted in this summary
- The claim of working with no prior interaction knowledge is stated without a described cold-start evaluation, which is precisely the setting where compound-protein predictors usually degrade. · noted in this summary
Who should read:Read this if you build compound-protein interaction models and want the argument for pretraining compound and protein embeddings on unlabelled data.
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Deep learning integration of molecular and interactome data for protein-compound interaction prediction
Narumi Watanabe, Yuuto Ohnuki, Yasubumi Sakakibara·Journal of CheminformaticsPeer-reviewed·May 1, 2021
- How to Approach Machine Learning-based Prediction of Drug/Compound-Target Interactions
Heval Ataş, Tunca Doğan·bioRxiv·May 1, 2022
- Yuel: Compound-Protein Interaction Prediction with High Generalizability
Jian Wang, Nikolay V. Dokholyan·bioRxiv·Jul 6, 2021
- DeepAffinity: Interpretable Deep Learning of Compound Protein Affinity through Unified Recurrent and Convolutional Neural Networks
Mostafa Karimi, Di Jia Wu, … Yang Shen·BioinformaticsPeer-reviewed·Feb 15, 2019
- CPGL: Prediction of compound-protein interaction by integrating graph attention network with long short-term memory neural network
Minghua Zhao, Min Yuan, … Steven X. Xu·IEEE Transactions on Computational Biology and BioinformaticsPeer-reviewed·Nov 29, 2022
- DeepERA: deep learning enables comprehensive identification of drug-target interactions via embedding of heterogeneous data
Le Li, Shayne D. Wierbowski, Haiyuan Yu·bioRxiv·Jan 27, 2023